CD40LG and COVID-19: Findings suggest that LFIAT can be used to assess SARS-CoV-2 immunity, while providing the first seroprevalence estimate for SARS-CoV-2 among healthy children and adolescents in Turkey, utilizing the COVID-19 IgG/IgM Rapid Test-KitA.